Guggenheim Cuts Eli Lilly and Company (NYSE:LLY) Price Target to $1,161.00

Eli Lilly and Company (NYSE:LLY) had its target price reduced by Guggenheim from $1,163.00 to $1,161.00 in a report published on Tuesday, MarketBeat.com reports. They currently have a buy rating on the stock.

A number of other research firms have also weighed in on LLY. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. HSBC reaffirmed a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. UBS Group began coverage on shares of Eli Lilly and Company in a report on Tuesday, January 6th. They set a “buy” rating and a $1,250.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. Finally, Scotiabank started coverage on shares of Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 target price on the stock. Four analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $1,174.61.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,087.63 on Tuesday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm has a market capitalization of $1.03 trillion, a P/E ratio of 53.21, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company’s 50-day moving average is $1,056.39 and its 200 day moving average is $878.04.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the firm posted $1.18 earnings per share. The company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Institutional Trading of Eli Lilly and Company

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Laurel Wealth Advisors LLC raised its holdings in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $8,827,714,000. Capital Research Global Investors grew its position in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Finally, Amundi raised its stake in shares of Eli Lilly and Company by 27.1% during the 3rd quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after acquiring an additional 964,675 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Launched a Phase 3b dosing study for retatrutide in obesity, advancing a leading obesity candidate toward optimized dosing and broader label/market potential. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Retatrutide trial data suggest potential knee osteoarthritis symptom benefit tied to weight loss — could expand clinical and commercial appeal beyond pure weight metrics. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: SURMOUNT‑REAL UK (phase 4) will provide real‑world tirzepatide data in obesity — useful for uptake, payer conversations and long‑term market sizing. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: FDA granted Breakthrough Therapy designation to sofetabart (mipitecan) for certain platinum‑resistant ovarian cancer patients — accelerates development path and raises long-term oncology upside. FDA Grants Breakthrough Therapy Tag to LLY’s Ovarian Cancer Candidate
• Positive Sentiment: Initiated a Phase 2 oral pain program for diabetic nerve pain — diversification of pipeline into high‑unmet‑need pain indications could add medium‑term value. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Neutral Sentiment: Announced a Phase 1 PET tracer imaging study to broaden oncology imaging capabilities — early stage, strategic but long‑timeline impact. Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study
• Neutral Sentiment: Confirmed Q4 2025 earnings date (Feb 4) — sets the calendar for next major catalyst and likely some pre‑earnings positioning. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Market commentary pieces (buy/preview, breakout) and an explainer on why LLY is up today summarize investor enthusiasm and momentum ahead of results; useful but opinion‑driven. Why Eli Lilly (LLY) stock is up today
• Negative Sentiment: Coverage notes Novo Nordisk’s new CEO is expected to intensify competition in obesity treatments — a reminder of pricing, market‑share and reimbursement risks. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.